A non-invasive, point-of-care (POC) system targets in vitro biomarkers of oxidative metabolism (OM) that are indicative of embryo viability.

Using technology based on biospectroscopy metabolomics (BSM) the non-invasive platform was developed to assess embryo and gamete viability for in vitro fertilization (IVF). The ViaTest-E system enables rapid identification and simultaneous analysis of multiple small molecule biomarkers of OM in a single sample. This analysis is expected to lead to the fast, accurate detection of viable embryos of high reproductive potential. The metabolomics platform has also been applied to therapeutic applications, as well as pharmacodiagnostics, drug discovery and development.

Molecular Biometrics (Chester, New Jersey, USA) ViaTest-E is a non-invasive, POC system that targets in vitro biomarkers of oxidative metabolism (OM) that are indicative of embryo viability. Complex interactions between the pro-oxidants and antioxidants are crucial in the maintenance of normal intracellular homeostasis. An imbalance in these reactions results in OM, which is known to affect the quality of spermatozoa, eggs, and embryos.

James Posillico, Ph.D., president and CEO of Molecular Biometrics commented, "Molecular Biometrics plans to offer IVF practitioners a rapid, objective method for assessing embryo viability that overcomes limitations associated with the current clinical practice of morphological examination. The selection of viable embryos is central to successful outcomes in IVF.”

Molecular Biometrics introduced the ViaTest-E for IVF and demonstrated the results of three clinical studies investigating the use of the test at the 23rd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) held in Lyon (France) from July 1-4, 2007.

http://www.gzjiayumed.com/en/index.asp